848852-15-3

Upstream product

• 874100-39-7 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-formyl-N-(2-hydroxyethoxy)benzamide 
• 203916-59-0 2,3,4-trifluoro-5-iodobenzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 848852-33-5 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-vinylbenzoic acid 
• 848852-32-4 2,3,4-trifluoro-5-vinylbenzoic acid 

Downstream Products

• 874101-00-5 CH4987655 

Relevant academic research and scientific papers

NOVEL CRYSTAL FORM OF 3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYL AMINO)-N-(2-HYDROXY-ETHOXY)-5-(3-OXO-[1,2]OXAZINAN-2-YLMETHYL)-BENZAMIDE

PROBLEM TO BE SOLVED: To provide an active pharmaceutical ingredient that is useful as MEK inhibitors and is stable physicochemically. SOLUTION: The present invention provides an educt I-type crystal of 3,4-difluoro-2-(2-fluoro-4-iodo-phenyl amino)-n-(2-hydroxy-ethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)-benzamide, having peaks with diffraction angles expressed by 2θ of 14.9, 16.9 and 23.1° (±0.2°) in a powder X-ray diffraction pattern measured using Cu Kα(1.54060?) as an X-ray source. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].